ASTHMAHALER |
EPPY |
JEXT |
RIDDOFAN |
BRONKAID MIST |
MEDIHALER-EPI |
SUS-PHRINE SULFITE FREE |
ANA-GUARD |
ADREN CO |
EMERADE |
ADRENALINE |
ADRENACLICK |
SYMJEPI |
TWINJECT 0.15 |
GPPE INH SOLN |
AUVI-Q |
ANA-KIT |
EPIPEN JR. |
RYBARVIN |
EPI E Z PEN JR |
SUS-PHRINE |
EPINEPHRINE HCL |
EPIPEN |
EPIPEN E Z PEN |
ANAPHYLACTIC SHOCK DRUG KIT |
NSC-62786 |
EPIPEN JR |
ADRENALIN |
EPINEPHRINE |
ASMA-VYDRIN |
SIMPLENE |
BROVON |
RIDDOBRON |
SOLN MADE TO RYBARVIN FOR |
SUS-PHRINE SULFITE-FREE |
TWINJECT 0.3 |
TWINJECT |
PRIMATENE MIST |
ANAPEN |
LEVO-METHYLAMINOETHANOLCATECHOL |
PRIMATENE |
(R)-(-)-ADNEPHRINE |
LEVOEPINEPHRINE |
(R)-EPINEPHRINE |
(-)-ADRENALINE |
(-)-EPINEPHRINE |
(R)-(-)-EPIRENAMINE |
L-EPINEPHRINE |
(R)-(-)-EPINEPHRINE |
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL |
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL |
(R)-(-)-ADRENALINE |
L-ADRENALINE |
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL |
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL |
(-)-3,4-DIHYDROXY-ALPHA-[2-(METHYLAMINO)ETHYL]BENZYL ALCOHOL |
(R)-4-[1-HYDROXY-2-(METHYLAMINO)ETHYL]-1,2-BENZENEDIOL |
(−)-ADRENALINE |
L-DETHYLAMINOETHANOLCATECHOL |
(R)-ADRENALINE |
(-)-3,4-DIHYDROXY-A-[2-(METHYLAMINO)ETHYL]BENZYL ALCOHOL |
L-1-(3,4-DIHYDROXYPHENYL)-2-METHYLAMINOETHANOL |
R-(-)-EPINEPHRINE |
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL |
4-[(1R)-1-HYDROXY-2-(METHYLAMINO)ETHYL]-1,2-BENZENEDIOL |
(-)-(R)-EPINEPHRINE |
L-EPIRENAMINE |
(R)-(−)-ADRENALINE |
chembl:CHEMBL679 |
rxcui:3992 |
pubchem.compound:5816 |
chemidplus:51-43-4 |
drugbank:00668 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | anestethic |
Drug Class | vasoconstrictor agents |
Drug Class | bronchodilator agents |
Year of Approval | approved before 1982 |
agonist (activating) |
Trial Name | transdermal lidocaine/epinephrine patch,Lidosite |
Novel drug target | Established target |
Mechanism of Interaction | Adrenergic receptor agonist |
agonist (activating) |
Trial Name | transdermal lidocaine/epinephrine patch,Lidosite |
Novel drug target | Established target |
Mechanism of Interaction | Adrenergic receptor agonist |
agonist (activating) |
Novel drug target | Established target |
Trial Name | transdermal lidocaine/epinephrine patch,Lidosite |
Mechanism of Interaction | Adrenergic receptor agonist |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
Novel drug target | Established target |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
Trial Name | transdermal lidocaine/epinephrine patch,Lidosite |
agonist (activating) |
Trial Name | transdermal lidocaine/epinephrine patch,Lidosite |
Novel drug target | Established target |
Mechanism of Interaction | Adrenergic receptor agonist |
agonist (activating) |
Direct Interaction | yes |
Mechanism of Interaction | Adrenergic receptor agonist |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
n/a |
Combination therapy | Articaine,Epinephrine |
Year of Approval | approved before 1982 |
Drug Class | bronchodilator agents |
Drug Class | vasoconstrictor agents |
Drug Indications | anestethic |
Drug Class | Small Molecule |
FDA Approval | approved |
C473 | NCI drug code |
D04PHC | TTD Drug ID |
CHEMBL679 | ChEMBL Drug ID |